Press Release: Phenomix Sciences and InformedDNA Partner to Advance Genetics-Driven Obesity Care
Launching at HLTH 2024, the groundbreaking partnership offers payers, health systems, employers, and life science organizations access to personalized obesity care and treatment planning based on a patient’s DNA…
InformedDNA partners with Phenomix Sciences to personalize obesity care, treatment and planning based on a patient’s DNA
Today, we’re excited to announce a groundbreaking new partnership with Phenomix Sciences, a precision medicine biotechnology company that applies data intelligence to the treatment of obesity. The collaboration integrates Phenomix’s MyPhenomeTM genetic obesity test with InformedDNA’s DNAimpactTM precision health platform, broadening access to genetics-based weight management care for payers, health systems, employers, and life sciences […]
Navigating Growing Demand for Genetic Services
Genetic counseling plays a critical role in accurately interpreting genetic test results, guiding decision-making for both patients and providers. Unfortunately, there are a limited number of genetic counselors. The answer lies in outsourcing genetic services as a way of tapping into external expertise and enhancing operational efficiency. This approach not only alleviates the burden on […]
6 Effective Strategies to Improve Diversity in Clinical Trials
Patient diversity and inclusion are essential to rare disease research progress. Why? Because people with the same disease may experience it differently. With a US population comprised of 40% racial and ethnic minorities[1],it’s essential that clinical trials reflect a variety of lived experiences, as well as characteristics like ethnicity, age, and gender, so that all […]
Overcoming Challenges of Incorporating Genetics into Clinical Trial Programs
To date, 760 orphan drugs have been approved by US and European agencies to treat nearly 7,000 identified rare diseases. With 80% having a genetic component, genetic testing and the use of its data have become essential ingredients to the successful diagnosis and treatment of rare diseases. Yet incorporating that genetic data into the clinical […]
The Cancer Letter: Joint byline, ‘Is gastrectomy indicated?’
A study recently published in JAMA sheds light on cancer risks associated with carrying germline CDH1 mutations, challenging previous, potentially inflated, lifetime cancer risk estimates. InformedDNA, FORCE: Facing Our Risk of Cancer Empowered, and No Stomach For Cancer, collaborate as patient advocates, educators, and experts to support individuals and families impacted by gastric cancer to help them navigate this complex genetic landscape. Subscribers to The Cancer Letter can login to read the full article.
Complexity of Genetic Testing Affects
Payment Integrity for Healthcare Ordering large multi-gene panel tests has increasingly become a common practice. Coupled with a limited amount of genetic testing billing codes and widely varying lab billing practices, this tactic leads to health plans overpaying for these tests. In this blog, we answer common questions posed by medical directors and claims management […]
Life Sciences Review: InformedDNA Featured Cover Story, Genetic Testing Edition
Actionable Genomic Insights for Successful Clinical Trials: A powerful genomic force is behind the growing success of clinical trials for drug development of rare diseases. InformedDNA CEO, Dr. Surya Singh shares their winning strategy, powered by their remote genetic experts and deep insights, that boosts accurate patient enrollment, improves retention rates, and empowers informed decision-making for life science clients.
Outsource Genetic Counseling to Reduce Backlog and Improve Patient Experience
As the demand for genetic counseling continues to rise, many health systems struggle to meet the needs of their patients. Delays in genetic counseling can have significant impacts, particularly for cancer patients where timely results are crucial. The National Society for Genetic Counselors (NSGC) estimates there are currently 5,629 genetic counselors in North America. With […]
The Cancer Letter: Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists
In a guest byline published in The Cancer Letter, InformedDNA’s chief medical officer and co-founder, Dr. Rebecca Sutphen describes the importance of paired tumor-germline testing in cancer patients and the critical role of genetics specialists in enhancing that care. Subscribers to The Cancer Letter can login to read the full article.
